Oncology Consortium

Impactful Education Through Innovative Engagement

roy.berger@theoncologyconsortium.com | (516) 729-0303
Service Hours
06:00:00 - 18:00:00

Urologic Oncology Consortium

Dr. Daneshmand earned his medical degree at the University of California, Davis, and completed his residency at the University of Southern California (USC) followed by a two-year fellowship in Urologic Oncology at the USC Norris Comprehensive Cancer Center. He spent almost 6 years at Oregon Health and Science University where he established the Section of Urologic Oncology as a center of excellence for treatment of bladder and testis cancers and earned early promotion to Associate Professor. He was then recruited to USC Institute of Urology as Director of Urologic Oncology. His main clinical and research interests include bladder cancer, advanced kidney cancer and testicular cancer. He has extensive experience in urinary diversion and reconstruction following surgical removal of the bladder (radical cystectomy) as well as nerve-sparing retroperitoneal lymph node dissection (RPLND) following chemotherapy for advanced testis cancer. He is one of the highest volume surgeons for these diseases on the west coast. He has been selected as one of “True Experts” in the Testicular Cancer Resource Center web site, and serves on the scientific advisory board of the bladder cancer advocacy network (BCAN). He has been elected to the Alpha Omega Alpha medical honor society, and has been designated one of the “America’s Top Cancer Doctors” and “America’s Top Urologists” and “America’s Top Doctors” for the past 6 years. He is an active member of the Society of Urologic Oncology, has presented over 200 abstracts at scientific meetings and authored over 180 peer-reviewed articles, reviews, and chapters.

Oncology Consortium | All Rights Reserved 2012-2017
Back to Top